Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.66
−$0.0012 · -0.18%
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Previous close
$0.66
−$0.0012 · -0.18%
Pre-market
$0.6499
−$0.0101 · -1.53%
Sep 14, 7:37 AM ET
Regular session · ET · Market data may be delayed.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Day range
Current $0.66
52-week range
Current $0.66
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
8
Overpriced
Sentiment
53
Mixed
Risk
64
High Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Day range
Current $0.66
52-week range
Current $0.66
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.41M USD | — | — | — | — |
| Cost of goods sold | 756.33K USD | — | — | 204.69K USD | — |
| Gross profit | 657.21K USD | — | — | −204.69K USD | — |
| Research and development | 27.78M USD | 41.76M USD | 26.45M USD | 42.33M USD | 38.96M USD |
| Selling, general, and administrative | 39.94M USD | 29.94M USD | 26.67M USD | 20.74M USD | 12.77M USD |
| Operating expenses | 67.72M USD | 71.7M USD | 53.13M USD | 62.87M USD | 51.73M USD |
| Interest income | 89.74K USD | 906.15K USD | 971.48K USD | — | — |
| Interest expense | 283.13K USD | 3.16M USD | 2.53M USD | 1.49M USD | 936.13K USD |
| Depreciation and amortization | 117.05K USD | 113.86K USD | 44.19K USD | 204.69K USD | 262.14K USD |
| Operating income | −67.06M USD | −71.7M USD | −53.13M USD | −63.07M USD | −51.73M USD |
| Net income | −62.42M USD | −75.37M USD | −58.98M USD | −66.05M USD | −53.16M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.80
324.24% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 14, 2024 | 1:20 | — | — |
Stock split | Mar 18, 2019 | 1:8 | — | — |
Effective Mar 14, 2024
1:20
Effective Mar 18, 2019
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
